Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Mutation profile in CMML undergoing allo-HSCT

Nico Gagelmann • 1 Sep 2020
EBMT 2020
Leukemia

Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the impact of mutation profile in chronic myelomonocytic leukemia (CMML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nico Gagelmann

The efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed myeloma after CAR-T
0:52
The efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed myeloma after CAR-T
Nico Gagelmann • 7 Feb 2025
Investigating the outcomes and cellular dynamics of cilta-cel versus ide-cel in R/R myeloma
1:04
Investigating the outcomes and cellular dynamics of cilta-cel versus ide-cel in R/R myeloma
Nico Gagelmann • 7 Feb 2025
Addressing equity and equality in access to CAR-T in Europe
1:08
Addressing equity and equality in access to CAR-T in Europe
Nico Gagelmann • 7 Feb 2025
How CAR-T will impact the future of myeloma treatment
0:52
How CAR-T will impact the future of myeloma treatment
Nico Gagelmann • 15 Feb 2024

Related Videos

Referral and transplant-timing decisions in AML: advice for community physicians
1:37
Referral and transplant-timing decisions in AML: advice for community physicians
Iskra Pusic • 11 Sep 2026
Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Integrating molecular testing into frontline treatment decisions in CLL
2:11
Integrating molecular testing into frontline treatment decisions in CLL
Kerry Rogers • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals